Jan. 23 (Bloomberg) -- Clal Biotechnology Industries Ltd. advanced the most in a week after a unit’s Phase IIb trial of an Alzheimer’s drug showed intermediate “positive” results.
The shares of the investment company gained as much as 2.3 percent, the biggest intraday increase since Jan. 16, and were 1 percent higher at 21.10 shekels as of 11:24 a.m. in Tel Aviv.
--Editors: Susan Lerner, Shanthy Nambiar
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com